Massachusetts-based biopharmaceutical company, Mustang Bio Inc., is focused on developing potential cures for hematologic cancers, solid tumors, and rare genetic diseases through innovative medical breakthrough technologies in cell and gene therapies. With a portfolio geared towards gene therapy programs targeting rare genetic disorders and chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies and solid tumors, Mustang Bio aims to revolutionize the biopharmaceutical industry's approach to treating these conditions. Among the company's groundbreaking therapies in development are "MB-107" and "MB-207," gene therapy programs targeting X-linked severe combined immunodeficiency, a rare genetic immune system condition which, without treatment, is lethal to affected patients before infancy. Additionally, the company has been actively researching development in other therapies such as "MB-102 CAR T" and "MB-103 CAR T" for acute myeloid leukemia, multiple myeloma, glioblastoma multiforme, and metastatic breast cancer to brain. Mustang Bio has also announced license agreements with established medical institutions, including Nationwide Children's Hospital, Mayo Clinic, Leiden University Medical Centre, SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. Mustang Bio was founded in 2015, and its headquarters are in Worcester, Massachusetts.